Free US stock insider buying and selling tracking with regulatory filing analysis for inside information on company health. We monitor corporate insider transactions because company officers often have the best understanding of their business prospects.
ProQR Therapeutics N.V. Ordinary Shares (PRQR), a clinical-stage biotech firm focused on RNA-based therapies for rare genetic diseases, is trading at $1.82 as of April 6, 2026, marking a 6.55% gain in recent trading. This analysis evaluates current price action, sector context, key technical support and resistance levels, and potential near-term scenarios for the stock, with no recent earnings data available for the company as of this publication. The recent upward move comes amid mixed sentimen
Is ProQR (PRQR) Stock Good for Short Term | Price at $1.82, Up 6.55% - Fundamentals
PRQR - Stock Analysis
4156 Comments
738 Likes
1
Ramsee
Registered User
2 hours ago
I read this and now I’m suspicious of my ceiling.
👍 33
Reply
2
Deshawndre
Insight Reader
5 hours ago
Are you trying to make the rest of us look bad? 😂
👍 81
Reply
3
Ezekai
Consistent User
1 day ago
Genius and humble, a rare combo. 😏
👍 189
Reply
4
Sarika
Trusted Reader
1 day ago
Regret not seeing this sooner.
👍 30
Reply
5
Ameiyah
Expert Member
2 days ago
I can’t be the only one reacting like this.
👍 71
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.